Abstract:525 Objectives The mesenchymal epithelial transition (c-Met) factor overexpression has been widely accepted as a potent biomarker for various of cancers such as glioblastoma, breast cancer, colorectal cancer, etc. c-Met inhibitor, which targets c-Met and further interferes with downstream signaling pathways, could serve as both diagnostic and therapeutic molecule by specifically binding with c-Met receptors. Until now small molecule based probes for c-Met imaging has not been reported. In previous studies, we have successfully synthesized c-Met inhibitor C21b with high c-Met receptor binding and suppressing functions and validated its tumor suppression capability. In the present study, we aim to develop a 68Ga labeled, C21b based PET probe for imaging of c-Met positive tumors such as glioblastoma which realize the potential for both glioblastoma detection and cancer therapy evaluation. Methods C21b molecule with NODAGA chelator was obtained through chemical synthesis and confirmed by MS and 1H-NMR. The resulting conjugate NODAGA-C21b was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. The PET probe was then characterized by HPLC analysis and subjected to mouse serum stability assay. The cell uptake and binding affinity tests of 68Ga-NODAGA-C21b were conducted using U87MG glioblastoma cells. Small animal PET imaging and biodistribution analysis were conducted on mice with c-Met overexpression (U87MG) and low expression (OVCAR3) tumor xenograft models (n=4 per group) after injection of approximately 7.4 MBq of 68Ga-NODAGA-C21b for up to 2 h after injection. Results 68Ga-NODAGA-C21b was successfully synthesized in high radiochemical purify (>99%) and yield (>98%) and demonstrated high stability in mouse serum for up to 2 h incubation. U87MG cells showed increased uptake of 68Ga-NODAGA-C21b tracer with longer incubation time (from 9.6 % at 15 min to 14.2 % at 2 h incubation). The uptake could be effectively reduced by excess unlabeled C21b and c-Met inhibitor Crizotinib (14.2 % vs. 2.4 % and 2.3 % for self-blocking and Crizotinib blocking, respectively, after 2 h incubation). Binding affinity assays revealed the Kd was 2.88 nM for U87MG cells. Small animal PET/CT imaging showed that 68Ga-NODAGA-C21b accumulated in U87MG tumor and retained at similar level during the 2 h monitoring (0.63, 0.46 and 0.45 %ID/g at 30, 60 and 120 min post injection). However, in OVCAR3 tumor, the signal was significantly lower from beginning and decreased dramatically afterwards (0.47, 0.26 and 0.20 %ID/g at 30, 60 and 120 min post injection). Biodistribution results exhibited that Tumor/Muscle (T/M) signal ratio increased from 3.18 to 4.15 in U87MG model at 2 h post injection time point while T/M ratio decreased from 2.29 to 1.66 in OVCAR3 model. And Tumor/Brain (T/B) signal ratio was higher in U87MG model than that of in OVCAR3 model at all three time points (2.53 vs. 1.56, 2.37 vs. 1.36 and 2.39 vs. 1.85). The probe was found to be mainly metabolized through liver and spleen. Conclusions c-Met targeted 68Ga-NODAGA-C21b is a novel small molecule based PET probe for imaging of c-Met overexpression tumors. Its ability to differentiate tumors with high and low c-Met expression in vivo holds the potential for stratification of patients for c-Met targeted cancer therapy. $$graphic_A6B47F64-40EB-4636-AEF2-5EF8FE968326$$

Preclinical Evaluation Of An F-18-Trifluoroborate Methionine Derivative For Glioma Imaging

Preclinical evaluation of an 18 F-trifluoroborate methionine derivative for glioma imaging

Evaluation of (2S,4S)-4-[18F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging

Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

18F-Trifluoromethylated D-Cysteine as a Promising New PET Tracer for Glioma Imaging: Comparative Analysis With MRI and Histopathology in Orthotopic C6 Models

Preclinical study of an 18F-labeled glutamine derivative for cancer imaging.

A bis-boron boramino acid PET tracer for brain tumor diagnosis

A Meta-Analysis on the Diagnostic Performance of (18)F-FDG and (11)C-Methionine PET for Differentiating Brain Tumors.

Optimization of Precursor Synthesis Conditions of (2S,4S)4–[18F]FPArg and Its Application in Glioma Imaging

[18F]FBQ-C2 As a Metabolically Stable Glutamine Derivative for Cancer Imaging

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

68Ga-Labeled Small Molecule Inhibitor for C-Met Targeted Pet Imaging of Tumor.

Comparison of: (2S,4R)-4-[18F]Fluoroglutamine, [11C]Methionine, and 2-Deoxy-2-[18F]Fluoro-D-Glucose and Two Small-Animal PET/CT Systems Imaging Rat Gliomas

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

Imaging Brain Metastasis Patients with 18F-(2S,4r)-4-fluoroglutamine.

Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells

RADI-17. EVALUATION OF A NOVEL 18F-LABELED TRYPTOPHAN TRACER FOR PET IMAGING OF BRAIN TUMORS IN A MEDULLOBLASTOMA MOUSE MODEL

Fluorine-18 labeling PEGylated 6-boronotryptophan for PET scanning of mice for assessing the pharmacokinetics for boron neutron capture therapy of brain tumors

PET Imaging of 18F-(2 S,4 R)4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients

Pilot Study of 18F-Bf3-tyr in Healthy Volunteers and Glioma Patients